BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16936982)

  • 21. Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.
    Hesse E; Musholt PB; Potter E; Petrich T; Wehmeier M; von Wasielewski R; Lichtinghagen R; Musholt TJ
    Br J Cancer; 2005 Sep; 93(5):565-70. PubMed ID: 16091757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
    Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
    Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients.
    Savagner F; Rodien P; Reynier P; Rohmer V; Bigorgne JC; Malthiery Y
    J Clin Endocrinol Metab; 2002 Feb; 87(2):635-9. PubMed ID: 11836297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recurrence of differentiated thyroid carcinoma without concomitant elevation of serum thyroglobulin: report of two cases].
    Velasco S; Solar A; Cruz F; Quintana JC; León A; Mosso L; Fardella C
    Rev Med Chil; 2007 Apr; 135(4):506-11. PubMed ID: 17554461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
    Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
    Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a sensitive and specific quantitative reverse transcription-polymerase chain reaction assay for blood thyroglobulin messenger ribonucleic acid in the follow-up of patients with differentiated thyroid carcinoma.
    Boldarine VT; Maciel RM; Guimarães GS; Nakabashi CC; Camacho CP; Andreoni DM; Mamone Mda C; Ikejiri ES; Kasamatsu TS; Crispim F; Hojaij FC; Hidal JT; Biscolla RP
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1726-33. PubMed ID: 20173019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
    Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-time quantitative PCR measurement of thyroglobulin mRNA in peripheral blood of thyroid cancer patients and healthy subjects.
    Li D; Butt A; Clarke S; Swaminathana R
    Ann N Y Acad Sci; 2004 Jun; 1022():147-51. PubMed ID: 15251954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
    Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
    Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference.
    Crane MS; Strachan MW; Toft AD; Beckett GJ
    Ann Clin Biochem; 2013 Sep; 50(Pt 5):421-32. PubMed ID: 23847033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
    Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood.
    Biscolla RP; Cerutti JM; Maciel RM
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3623-7. PubMed ID: 11061512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?
    Verburg FA; Lips CJ; Lentjes EG; de Klerk JM
    Br J Cancer; 2004 Jul; 91(2):200-4. PubMed ID: 15213710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.
    Schlumberger M; Berg G; Cohen O; Duntas L; Jamar F; Jarzab B; Limbert E; Lind P; Pacini F; Reiners C; Sánchez Franco F; Toft A; Wiersinga WM
    Eur J Endocrinol; 2004 Feb; 150(2):105-12. PubMed ID: 14763906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody.
    Li YR; Tseng CP; Hsu HL; Lin HC; Chen YA; Chen ST; Liou MJ; Lin JD
    Clin Chim Acta; 2018 Feb; 477():74-80. PubMed ID: 29229463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
    Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
    Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?
    Zöphel K; Wunderlich G; Smith BR
    Thyroid; 2003 Sep; 13(9):861-5. PubMed ID: 14588100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.